These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29581115)

  • 1. Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.
    Hirayama T; Miyazaki T; Yamagishi Y; Mikamo H; Ueda T; Nakajima K; Takesue Y; Higashi Y; Yamamoto Y; Kimura M; Araoka H; Taniguchi S; Fukuda Y; Matsuo Y; Furutani A; Yamashita K; Takazono T; Saijo T; Shimamura S; Yamamoto K; Imamura Y; Izumikawa K; Yanagihara K; Kohno S; Mukae H
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10.
    Chen CY; Huang SY; Tang JL; Tsay W; Yao M; Ko BS; Chou WC; Tien HF; Hsueh PR
    J Antimicrob Chemother; 2013 Nov; 68(11):2632-5. PubMed ID: 23766486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates.
    Lockhart SR; Messer SA; Pfaller MA; Diekema DJ
    J Clin Microbiol; 2009 Jan; 47(1):242-4. PubMed ID: 19036938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum.
    Saleh Q; Kovács R; Kardos G; Gesztelyi R; Kardos T; Bozó A; Majoros L
    Microb Drug Resist; 2017 Sep; 23(6):764-770. PubMed ID: 28072553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Antifungal Susceptibility Profile of Candida guilliermondii and Candida fermentati from a Multicenter Study in China.
    Cheng JW; Yu SY; Xiao M; Wang H; Kudinha T; Kong F; Xu YC
    J Clin Microbiol; 2016 Aug; 54(8):2187-9. PubMed ID: 27252461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
    Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
    Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
    Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
    [No Abstract]   [Full Text] [Related]  

  • 8. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trend of susceptibility testing of clinical isolates of Candida species from aseptic samples in hospitals in Saitama prefecture].
    Tarumoto N; Watanabe N; Tanabe K; Hashikita G; Takahashi S; Yuki A; Hirose Y; Sekine S; Kanoh I; Shimojima M; Kaneda M; Yamaguchi T; Ohno H; Miyazaki Y; Maesaki S
    Jpn J Antibiot; 2014 Aug; 67(4):215-21. PubMed ID: 25420317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reidentification and antifungal susceptibility profile of Candida guilliermondii and Candida famata clinical isolates from a culture collection in Argentina.
    Taverna CG; Córdoba S; Vivot M; Szusz W; Vivot W; Bosco-Borgeat ME; Davel G
    Med Mycol; 2019 Apr; 57(3):314-323. PubMed ID: 29955881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
    Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Zaragoza O; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins.
    Chassot F; Venturini TP; Piasentin FB; Rossato L; Fiorini A; Svidzinski TI; Alves SH
    Mycopathologia; 2016 Oct; 181(9-10):663-70. PubMed ID: 27318852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
    Barchiesi F; Spreghini E; Tomassetti S; Della Vittoria A; Arzeni D; Manso E; Scalise G
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2719-27. PubMed ID: 16870764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Confirmation of the Relationship between Candida guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility.
    Dudiuk C; Macedo D; Leonardelli F; Theill L; Cabeza MS; Gamarra S; Garcia-Effron G
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242659
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
    García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.
    Marcos-Zambrano LJ; Puig-Asensio M; Pérez-García F; Escribano P; Sánchez-Carrillo C; Zaragoza O; Padilla B; Cuenca-Estrella M; Almirante B; Martín-Gómez MT; Muñoz P; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.
    Paredes K; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Guarro J
    Rev Iberoam Micol; 2015; 32(1):34-9. PubMed ID: 24594291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.